A maker of surgical products that repair damaged peripheral nerves, Axogen's lineup includes the Avance Nerve Graft (processed human nerve tissue) and the Axoguard line of porcine-based connectors, protectors, and caps used by surgeons to restore feeling and movement. The business grew out of technology licensed from the University of Florida and took its current form after a 2011 merger, with the FDA approving Avance as a licensed biologic in 2025. A neat quirk: before Avance, the standard repair often meant cutting a healthy nerve from elsewhere in the patient's own body, so the fix created a new injury.
Axogen Q2 revenue rose 23% to $69.7M in the first full quarter of Avance Nerve Graft's commercial launch as a licensed biologic, but gross margin fell to 72.7%.
The first full quarter of Avance Nerve Graft's commercial launch as a licensed biologic delivered Axogen's highest quarterly on record. Revenue rose 23.1% to $69.7 million, driven by higher unit volume and favorable pricing, but fell 1.5 points to 72.7% as sales of higher-cost biologic products and long grafts for breast reconstruction procedures weighed on product costs. The company is debt-free after repaying its term loan, but the path to sustained profitability now depends on whether volume growth can outrun the margin pressure from its shifting product mix.
Key takeaways
rose 23.1% to $69.7 million, the highest quarterly revenue in the periods shown, driven by unit volume increases and favorable pricing as the company began the full commercial launch of Avance Nerve Graft as a licensed biologic.
fell 1.5 points to 72.7%, which management attributed to higher product costs from increased sales of higher-cost biologic Avance products and long Avance grafts used in breast Resensation procedures, partially offset by lower write-offs.
Section summaries
Management's Discussion and Analysis
Q2 2026 revenue rose 23.1% to $69.7M on higher unit volume, while gross margin dipped to 72.7% on elevated biologic product costs.
⌄
grew 23.1% to $69.7M in Q2 2026, driven by unit volume increases and favorable pricing.
declined to 72.7% from 74.2% due to higher product costs from increased sales of higher-cost biologic Avance products and long Avance grafts for breast Resensation procedures, partially offset by lower .
rose 30.9% to $52.8 million, led by higher compensation and tied to sales growth and headcount expansion as the company invests behind the post-approval launch.
Other income swung to a $0.6 million net gain from a $1.1 million loss a year ago, primarily because dropped $2.0 million after the company fully repaid and terminated its in Q1 2026.
Cash and investments totaled $111.4 million at quarter-end, up from $101.6 million in Q1, reflecting the $133.3 million equity raise completed after the 2025 fiscal year-end; management stated existing resources are sufficient to fund operations for at least twelve months.
The company reported no material changes to the risk factors disclosed in its 2025 10-K, and the confirmatory study protocol for Avance's accelerated-approval indications was due to the FDA by February 2026.
What changed
The commercial launch of Avance Nerve Graft as a licensed biologic, flagged as a key watch item after the December 2025 FDA approval, began in early Q2 2026 and drove a 23.1% increase — the fastest quarterly growth since Q2 2024 — though the product mix shift toward higher-cost biologic grafts pressured to 72.7%, its lowest level since Q1 2025.
, which was expected to improve as one-time BLA approval costs rolled off, instead declined 2.5 points sequentially from 75.2% in Q1 2026, as higher product costs from the Avance product mix more than offset the benefit of lower write-offs.
Operating expense growth accelerated to 30.9% , up from 34% in Q1 2026, as the company continued to invest in compensation and marketing behind the post-approval launch; the $133.3 million equity raise and debt repayment have eliminated interest and -participation payments, but the path to sustained profitability now hinges on whether revenue growth can outpace the rising cost base.
The confirmatory study protocol for Avance's accelerated-approval indications, due to the FDA by February 2026, was not explicitly addressed in the filing, leaving the status of that regulatory milestone unclear.
What to watch
trajectory in Q3 2026, to see if the 72.7% level represents a new baseline driven by the shift toward higher-cost biologic Avance products and long grafts for Resensation procedures, or if production efficiencies at the Axogen Processing Center can offset the mix pressure.
growth in Q3 2026, the second full quarter of the Avance Nerve Graft commercial launch, to gauge whether the 23.1% pace is sustainable and whether the new CMS Level 3 Nerve Procedure Code and payer coverage decisions continue to support surgeon adoption.
Operating expense growth relative to , now that interest and revenue-participation payments are eliminated, to assess whether the company can narrow operating losses or reach sustained profitability as it invests behind the launch.
Progress on the confirmatory study for Avance's accelerated-approval indications, including any update on the protocol submission to the FDA, to assess the risk to the indications for sensory nerve gaps over 25mm and mixed/motor nerve discontinuities.
Total operating expenses rose 30.9% to $52.8M, led by higher compensation and tied to sales growth and headcount expansion.
Other income swung to a net $0.6M gain from a $1.1M loss last year, primarily due to a $2.0M drop in after debt extinguishment.
Cash and investments totaled $111.4M at quarter-end, bolstered by $133.3M in net equity offering proceeds, with management expecting sufficient liquidity to fund operations for at least the next twelve months.
Quantitative and Qualitative Disclosures About Market Risk
For a discussion of our market risks, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” included in our 2025 Annual Report on Form 10-K.
⌄
For a discussion of our market risks, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” included in our 2025 Annual Report on Form 10-K.
As disclosed in Note 14 - Commitments and Contingencies in the Notes to the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, we are engaged in certain legal proceedings, and the disclosure set forth in Note 14 - Commitments and Continge…
⌄
As disclosed in Note 14 - Commitments and Contingencies in the Notes to the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, we are engaged in certain legal proceedings, and the disclosure set forth in Note 14 - Commitments and Contingencies relating to legal proceedings is incorporated herein by reference.
There have been no material changes to the risk factors disclosed in our 2025 Annual Report on Form 10-K. Any investment in our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Quarter…
⌄
There have been no material changes to the risk factors disclosed in our 2025 Annual Report on Form 10-K. Any investment in our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Quarterly Report on Form 10-Q, including our unaudited interim condensed consolidated financial statements and accompanying notes, our Annual Report on Form 10-K for the year ended December 31, 2025, including our financial statements and related notes contained therein, and the additional information in the other reports we file with the SEC. These risks may result in material harm to our business and our financial condition and results of operations. In this event, the market price of our common stock may decline, and you could lose part or all of your investment. Additional risks that we currently believe are immaterial may also impair our business operations. Our business, financial condition and future prospects and the trading price of our common stock could be harmed as a result of any of these risks.